D.A. Davidson & CO. Takes Position in Anavex Life Sciences Corp. (NASDAQ:AVXL)

D.A. Davidson & CO. bought a new stake in Anavex Life Sciences Corp. (NASDAQ:AVXL) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 11,385 shares of the biotechnology company’s stock, valued at approximately $122,000.

Several other institutional investors and hedge funds have also bought and sold shares of the stock. Creative Planning grew its stake in Anavex Life Sciences by 54.2% in the third quarter. Creative Planning now owns 39,871 shares of the biotechnology company’s stock valued at $226,000 after purchasing an additional 14,010 shares in the last quarter. Private Advisor Group LLC boosted its holdings in shares of Anavex Life Sciences by 10.3% in the 3rd quarter. Private Advisor Group LLC now owns 47,413 shares of the biotechnology company’s stock valued at $269,000 after buying an additional 4,442 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its holdings in Anavex Life Sciences by 64.0% during the third quarter. China Universal Asset Management Co. Ltd. now owns 16,309 shares of the biotechnology company’s stock worth $93,000 after buying an additional 6,366 shares during the last quarter. Forum Financial Management LP bought a new stake in Anavex Life Sciences during the third quarter worth $200,000. Finally, Balentine LLC acquired a new stake in Anavex Life Sciences in the third quarter valued at $115,000. Institutional investors own 31.55% of the company’s stock.

Anavex Life Sciences Trading Down 2.7 %

AVXL opened at $7.85 on Friday. The stock’s fifty day simple moving average is $9.90 and its 200 day simple moving average is $7.83. Anavex Life Sciences Corp. has a 1-year low of $3.25 and a 1-year high of $14.44. The stock has a market cap of $667.72 million, a PE ratio of -14.27 and a beta of 0.69.

Anavex Life Sciences (NASDAQ:AVXL) last issued its quarterly earnings data on Wednesday, February 12th. The biotechnology company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.17) by $0.03. Equities analysts forecast that Anavex Life Sciences Corp. will post -0.69 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on AVXL. D. Boral Capital restated a “buy” rating and set a $46.00 price objective on shares of Anavex Life Sciences in a research note on Wednesday, February 12th. HC Wainwright reiterated a “buy” rating and set a $42.00 price target on shares of Anavex Life Sciences in a report on Tuesday, February 18th.

Anavex Life Sciences Profile

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.